58
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy

, &
Pages 423-428 | Published online: 28 Apr 2014

References

  • KhoslaSBurrDCauleyJBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2007221479149117663640
  • CardwellCRAbnetCCCantwellMMMurrayLJExposure to oral bisphosphonates and risk of esophageal cancerJAMA201030465766320699457
  • ShaneEBurrDEbelingPRAtypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2010252267229420842676
  • Park-WyllieLYMamdaniMMJuurlinkDNBisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older womenJAMA201130578378921343577
  • MeierRPPernegerTVSternRRizzoliRPeterREIncreasing occurrence of atypical femoral fractures associated with bisphosphonate useArch Intern Med201217293093622732749
  • WattsNBBilezikianJPCamachoPMAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosisEndocr Pract201016Suppl 313721224201
  • US Food Drug AdministrationSummary minutes of the joint meeting of the Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee992011 [cited October 8, 2013]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM278481.pdfAccessed January 27, 2014
  • WhitakerMGuoJKehoeTBensonGBisphosphonates for osteoporosis – where do we go from here?N Engl J Med20123662048205122571168
  • American Association of Clinical EndocrinologistsAACE Responds to FDA Hearing on Bisphosphonates [cited October 8, 2013]. Available from: http://media.aace.com/press-release/aace-responds-fda-hearing-bisphosphonatesAccessed January 27, 2014
  • National Osteoporosis FoundationClinician’s Guide to Prevention and Treatment of OsteoporosisWashington, DCNational Osteoporosis Foundation2013
  • DiabDLWattsNBBisphosphonates in the treatment of osteoporosisEndocrinol Metab Clin North Am20124148750622877426
  • KanisJAWorld Health Organization Scientific GroupAssessment of Osteoporosis at the Primary Health-Care Level Technical report of the World Health Organization Collaborating Centre for Metabolic Bone DiseasesSheffield, UKUniversity of Sheffield2007
  • IMS National Prescription Audit22013
  • LookerACMeltonLJ3rdHarrisTBBorrudLGShepherdJAPrevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES IIIJ Bone Miner Res201025647119580459
  • LookerACBorrudLGDawson-HughesBShepherdJAWrightNCOsteoporosis or low bone mass at the femur neck or lumbar spine in older adults: United States, 2005–2008NCHS Data Brief2012931822617299
  • RianonNAnandDRasuRChanging trends in osteoporosis care from specialty to primary care physiciansCurr Med Res Opin20132988188823718160
  • NyeAMHamrickIRauchAPoundMWSheltonPSDocumenting the use of calcium supplements with oral bisphosphonatesConsult Pharm201328313823315280
  • International Society of clinical Densitometry2007ISCD Official Positions – Adult [cited October 8, 2013]. Available from: http://www.iscd.org/official-positions/2007-iscd-official-positions-adult
  • KanisJAJohnellOOdenAJohanssonHMcCloskeyEFRAX and the assessment of fracture probability in men and women from the UKOsteoporos Int20081938539718292978
  • SnellingAMCrespoCJSchaefferMSmithSWalbournLModifiable and nonmodifiable factors associated with osteoporosis in postmenopausal women: results from the Third National Health and Nutrition Examination Survey, 1988–1994J Womens Health Gend Based Med200110576511224945